A share price of Regeneron Pharmaceuticals, Inc [REGN] is currently trading at $785.17, up 0.75%. An important factor to consider is whether the stock is rising or falling in short-term value. The REGN shares have gain 5.20% over the last week, with a monthly amount glided 3.87%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Regeneron Pharmaceuticals, Inc [NASDAQ: REGN] stock has seen the most recent analyst activity on December 03, 2025, when Morgan Stanley downgraded its rating to a Equal-Weight but kept the price target unchanged to $767 for it. On November 24, 2025, HSBC Securities initiated with a Buy rating and assigned a price target of $255 on the stock. Scotiabank started tracking the stock assigning a Sector Perform rating and suggested a price target of $650 on November 13, 2025. Rothschild & Co Redburn initiated its recommendation with a Buy and recommended $890 as its price target on August 14, 2025. Argus downgraded its rating to Hold for this stock on June 30, 2025. In a note dated May 30, 2025, Wells Fargo downgraded an Equal Weight rating on this stock but restated the target price of $580.
Regeneron Pharmaceuticals, Inc experienced fluctuations in its stock price throughout the past year between $476.49 and $790.98. Currently, Wall Street analysts expect the stock to reach $782.88 within the next 12 months. Regeneron Pharmaceuticals, Inc [NASDAQ: REGN] shares were valued at $785.17 at the most recent close of the market. An investor can expect a potential drop of -0.29% based on the average REGN price forecast.
Analyzing the REGN fundamentals
Trailing Twelve Months sales for Regeneron Pharmaceuticals, Inc [NASDAQ:REGN] were 14.25B which represents 0.90% growth. Gross Profit Margin for this corporation currently stands at 0.85% with Operating Profit Margin at 0.26%, Pretax Profit Margin comes in at 0.36%, and Net Profit Margin reading is 0.32%. To continue investigating profitability, this company’s Return on Assets is posted at 0.11, Equity is 0.15 and Total Capital is 0.1. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.09.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 777.20 points at the first support level, and at 769.22 for the second support level. However, for the 1st resistance point, the stock is sitting at 792.95, and for the 2nd resistance point, it is at 800.72.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Regeneron Pharmaceuticals, Inc [NASDAQ:REGN] is 4.06. On the other hand, the Quick Ratio is 3.33, and the Cash Ratio is 0.57. Considering the valuation of this stock, the price to sales ratio is 5.79, the price to book ratio is 2.67 and price to earnings (TTM) ratio is 18.80.
Transactions by insiders
Recent insider trading involved Bassler Bonnie L, Director, that happened on Nov 20 ’25 when 760.0 shares were sold. Director, Bassler Bonnie L completed a deal on Nov 20 ’25 to buy 760.0 shares. Meanwhile, VP Controller Pitofsky Jason sold 431.0 shares on Nov 07 ’25.
